ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,239.08
0.18%
Dow Jones
42,297.12
0.86%
Gold vs US Dollar
2,666.12
-0.09%
Brent Oil
79.685
-0.74%
Bitcoin
96,629.10
2.24%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Biohaven Ltd (BHVN)

  7. Biohaven Ltd (BHVN) News

Biohaven (BHVN)

Biohaven Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:BHVN
DateTimeSourceHeadlineSymbolCompany
13/01/202516:16Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
13/01/202516:15PR Newswire (US)Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation PoNYSE:BHVNBiohaven Ltd
13/01/202501:04GlobeNewswire Inc.Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC ProgramsNYSE:BHVNBiohaven Ltd
07/01/202522:54PR Newswire (US)Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNYSE:BHVNBiohaven Ltd
16/12/202412:30PR Newswire (US)Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program UpdatesNYSE:BHVNBiohaven Ltd
06/12/202412:30PR Newswire (US)Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual MeetingNYSE:BHVNBiohaven Ltd
25/11/202412:30PR Newswire (US)Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and ObesityNYSE:BHVNBiohaven Ltd
12/11/202421:16Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
12/11/202421:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
12/11/202421:05PR Newswire (US)Biohaven Reports Third Quarter 2024 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
02/10/202420:18Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
02/10/202420:05PR Newswire (US)Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNYSE:BHVNBiohaven Ltd
01/10/202420:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
01/10/202410:00PR Newswire (US)Biohaven Announces Pricing of $250 Million Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
30/09/202421:29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
30/09/202420:05PR Newswire (US)Biohaven Announces Proposed Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
30/09/202411:30PR Newswire (US)Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of MigraineNYSE:BHVNBiohaven Ltd
24/09/202410:15IH Market NewsVisa Faces Monopoly Lawsuit; Meta Introduces Celebrity Voices for Chatbot; Stellantis on the Hunt for New CEONYSE:BHVNBiohaven Ltd
23/09/202413:11Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
23/09/202411:30PR Newswire (US)Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)NYSE:BHVNBiohaven Ltd
20/09/202423:09PR Newswire (US)Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar AtaxiaNYSE:BHVNBiohaven Ltd
16/08/202420:35Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
16/08/202420:31Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NYSE:BHVNBiohaven Ltd
16/08/202420:25Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
16/08/202420:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
09/08/202420:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
08/08/202420:17Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
08/08/202420:05PR Newswire (US)Biohaven Reports Second Quarter 2024 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
29/05/202411:30PR Newswire (US)Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D DayNYSE:BHVNBiohaven Ltd
29/05/202411:15PR Newswire (US)Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial TumorsNYSE:BHVNBiohaven Ltd
 Showing the most relevant articles for your search:NYSE:BHVN

Your Recent History

LSE
CARD
Card Factory
LSE
JD.
Jd Sports Fashion
LSE
SCLP
Scancell
LSE
POS
Plexus
LSE
BOO
Boohoo
LSE
AAZ
Anglo Asian Mining
LSE
BIRD
Blackbird
LSE
SBTX
Skinbiotherapeutics
LSE
GLEN
Glencore
LSE
TW.
Taylor Wimpey
LSE
VAST
Vast Resources
LSE
TERN
Tern
LSE
TRLS
Trellus Health
LSE
OCDO
Ocado
LSE
JLP
Jubilee Metals
LSE
SRSP
Sirius Petroleum
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads